Pure Biologics (WAR:PUR) Treasury Stock : zł0.00 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Pure Biologics Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Pure Biologics's treasury stock for the quarter that ended in Sep. 2024 was zł0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Pure Biologics Treasury Stock Historical Data

The historical data trend for Pure Biologics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pure Biologics Treasury Stock Chart

Pure Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Get a 7-Day Free Trial

Pure Biologics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Pure Biologics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Pure Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pure Biologics SA (WAR:PUR) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

ul. Dunska 11, Wroclaw, POL, 54-427

Website

http://www.purebiologics.pl

Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.

Pure Biologics Headlines

No Headlines